Literature DB >> 9690547

Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant.

P Mueller1, P Carroll, E Bowers, D Moore, M Cher, J Presti, M Wessman, M G Pallavicini.   

Abstract

BACKGROUND: Low frequency epithelial cells occur in bone marrow aspirates of 25-50% of patients with locally confined prostate carcinoma. It is assumed that bone marrow epithelial cells derive from the primary tumor; however, it has not been established unequivocally that they are tumor cells. Immunofluorescence approaches were used to quantify the frequency of epithelial cells in bone marrow aspirates from prostate carcinoma patients and genotypic analyses were used to determine whether they contained numeric aberrations of chromosomes 1, 7, and 8.
METHODS: Epithelial cells in bone marrow aspirates collected after radical prostatectomy were visualized using fluorescence microscopy and fluorophore-linked antibodies against cytokeratin 8,18 (CK) and prostate specific antigen (PSA). Antibodies specific for proliferating nuclear cell antigen (PCNA) were used to evaluate the cycling status of discriminated cells. Copies of chromosomes 1, 7, and 8 in the discriminated epithelial cells were quantified using fluorescence in situ hybridization.
RESULTS: CK+ cells were present in bone marrow aspirates from 30 of 66 patients (approximately 45%) at a median frequency of 1.4 CK+ cells/10(5) mononuclear cells. Few CK+ epithelial cells in the bone marrow aspirates coexpressed PSA and none of the CK+ cells expressed PCNA. Approximately 70-75% of the CK+ cells contained 7 and 8 aneusomies. Gains of chromosome 1 occurred in 42% of the CK+ cells.
CONCLUSIONS: The majority of CK+ cells in bone marrow aspirates collected after surgery are cytogenetically aberrant, which is consistent with a primary tumor origin. The prevalence and frequency of CK+ cells is independent of tumor stage/grade and androgen treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690547

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates.

Authors:  A Forus; H K Høifødt; G E Overli; O Myklebost; O Fodstad
Journal:  Mol Pathol       Date:  1999-04

2.  Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses.

Authors:  José Ignacio Martín-Subero; Ilse Chudoba; Lana Harder; Stefan Gesk; Werner Grote; Francisco Javier Novo; María José Calasanz; Reiner Siebert
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 3.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

Review 4.  The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?

Authors:  Heike Allgayer; Julio A Aguirre-Ghiso
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

5.  Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.

Authors:  Ilona N Holcomb; Douglas I Grove; Martin Kinnunen; Cynthia L Friedman; Ian S Gallaher; Todd M Morgan; Cassandra L Sather; Jeffrey J Delrow; Peter S Nelson; Paul H Lange; William J Ellis; Lawrence D True; Janet M Young; Li Hsu; Barbara J Trask; Robert L Vessella
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

6.  Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters.

Authors:  Anders Carlsson; Peter Kuhn; Madelyn S Luttgen; Kevin Keomanee-Dizon; Patricia Troncoso; Paul G Corn; Anand Kolatkar; James B Hicks; Christopher J Logothetis; Amado J Zurita
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

Review 7.  Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients.

Authors:  S Braun; N Harbeck
Journal:  Breast Cancer Res       Date:  2001-06-28       Impact factor: 6.466

Review 8.  Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives.

Authors:  Volkmar Müller; Klaus Pantel
Journal:  Breast Cancer Res       Date:  2004-09-29       Impact factor: 6.466

Review 9.  Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management.

Authors:  Nigel P Murray
Journal:  Biol Res       Date:  2018-09-04       Impact factor: 5.612

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.